Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Director · 10% owner | December 23, 2020 | May 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Werewolf Therapeutics, Inc.
Report date December 23, 2020 · Filed May 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,068,909 |
Last balance in matching sequence
After 2021-05-04 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-05-04 · Conversion · Acquired 1,318,311 · Balance 1,318,311 F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. Row 2 · 2021-05-04 · Conversion · Acquired 438,098 · Balance 1,756,409 F3: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. Row 3 · 2021-05-04 · Purchase · Acquired 312,500 · Balance 2,068,909 F2: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 3,797,921 |
Reported balance
After 2020-12-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-23 · Purchase · Acquired 3,797,921 · Balance 3,797,921 F4: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-04 · Conversion · Disposed 3,797,921 · Balance 0 F3: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-04 · Conversion · Disposed 11,428,570 · Balance 0 F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC.
F3: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F4: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries B Preferred Stock · Derivative | 3,797,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018116 · doc4.xml · derivative · entry 6 Asanuma Sakae · CIK 0001857822 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 438,098 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · derivative.exercise_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · derivative.expiration_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries A Preferred Stock · Derivative | 11,428,570 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018116 · doc4.xml · derivative · entry 5 Asanuma Sakae · CIK 0001857822 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,318,311 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | PurchaseCommon Stock | 312,500 | $16.00 | $5,000,000.00 |
DisclosureSEC source: 0000899243-21-018116 · doc4.xml · nonDerivative · entry 3 Asanuma Sakae · CIK 0001857822 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,068,909 F2 · ownership.nature: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 438,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018116 · doc4.xml · nonDerivative · entry 2 Asanuma Sakae · CIK 0001857822 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,756,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 1,318,311 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018116 · doc4.xml · nonDerivative · entry 1 Asanuma Sakae · CIK 0001857822 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,318,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. Read SEC document |
| December 23, 2020 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | PurchaseSeries B Preferred Stock · Derivative | 3,797,921 | $0.92 | $3,499,404.41 |
DisclosureSEC source: 0000899243-21-018116 · doc4.xml · derivative · entry 4 Asanuma Sakae · CIK 0001857822 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,797,921 Underlying: Common Stock · 438,098 shares Expires not disclosed F4 · derivative.exercise_price: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · derivative.exercise_date: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · derivative.expiration_date: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.